This is a working overview of GIP receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-15. Anything still debated is marked as such rather than presented as settled.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
== Biofilm characteristics == The formation of the cellulose pellicle at the surface of the broth yields a product with unique characteristics that both bacteria and consumers find advantageous. Upon inoculation into the culture, bacteria such as Acetobacter immediately begin pulling glucose molecules together outside of the cell and joining them via β(1-4) linkages to form long, slender structures extending from their cell membranes called fibrils. The nanocellulose composing these fibrils demonstrates great strength and stability while still allowing hydrophilic interactions and biocompatibility, making it a great resource for the culture to use. A variety of inter and intramolecular bonding events join numerous fibrils together into the final, much larger structures known as microfibrils; because of the integrity of the microfibrils and the organized, linear nature of cellulose bonds, the resulting biofilm can also be referred to as a matrix or mat. This biofilm is a natural defense mechanism for the co-culture, and can withstand extreme conditions such as temperature and UV radiation. Two additional characteristics of the nanofibril cellulose SCOBY—its high purity and crystallinity—are currently a target in biomedical research in the formation of biocompatible tissue scaffolds, cardiovascular components such as blood vessels, bone grafts, and connective tissue replacements. The nanocellulose fibrils can also be extracted via acid hydrolysis and used in the food packaging, clothing, and wastewater treatment industries.
A large factor controlling the redox budget of early Earth's atmosphere is the rate of atmospheric escape of H2 after Earth's formation. Atmospheric escape – common to young, rocky planets — occurs when gases in the atmosphere have sufficient kinetic energy to overcome gravitational energy. It is generally accepted that the timescale of hydrogen escape is short enough such that H2 made up < 1% of the atmosphere of prebiotic Earth, but, in 2005, a hydrodynamic model of hydrogen escape predicted escape rates two orders of magnitude lower than previously thought, maintaining a hydrogen mixing ratio of 30%. A hydrogen-rich prebiotic atmosphere would have large implications for Miller–Urey synthesis in the Hadean and Archean, but later work suggests solutions in that model might have violated conservation of mass and energy. That said, during hydrodynamic escape, lighter molecules like hydrogen can "drag" heavier molecules with them through collisions, and recent modeling of xenon escape has pointed to a hydrogen atmospheric mixing ratio of at least 1% or higher at times during the Archean. Taken together, the view that early Earth's atmosphere was weakly reducing, with transient instances of highly-reducing compositions following large impacts is generally supported.
Diaphoresis due to ectopic catecholamine is a classic symptom of a pheochromocytoma, a rare tumor of the adrenal gland. Acetylcholinesterase inhibitors (e.g. some insecticides) also cause contraction of sweat gland smooth muscle leading to diaphoresis. Mercury is well known for its use as a diaphoretic, and was widely used in the 19th and early 20th century by physicians to "purge" the body of an illness. However, due to the high toxicity of mercury, secondary symptoms would manifest, which were erroneously attributed to the former disease that was being treated with mercurials. Infantile acrodynia (childhood mercury poisoning) is characterized by excessive perspiration. A clinician should immediately consider acrodynia in an afebrile child who is sweating profusely. Some people can develop a sweat allergy. The allergy is not due to the sweat itself but instead to an allergy-producing protein secreted by bacteria found on the skin. Tannic-acid has been found to suppress the allergic response along with showering.
Traditional nickel catalyst methanizers are designed to only convert CO and CO2 to methane. Due to this limitation, deactivation commonly occurs when other compounds are present in the sample matrix, such as olefins and sulfur containing compounds. Thus, the use of methanizers often requires complex valve systems that may include backflush and heartcutting. Nickel catalyst replacement and conditioning steps are time consuming and require operator skill to perform properly.
Prodynorphin, also known as proenkephalin B, is an opioid polypeptide hormone involved with chemical signal transduction and cell communication. The gene for prodynorphin is expressed in the endometrium and the striatum, and its gene map locus is 20pter-p12. Prodynorphin is a basic building-block of dynorphins, the chemical messengers in the brain that appear most heavily involved in the anticipation and experience of pain, stress responses, as well appetite and temperature regulation, as well as neoendorphins. The gene is thought to influence perception, as well as susceptibility to drug dependence, and is expressed more readily in human beings than in other primates.
Sources: en.wikipedia.org
Cysteine proteases, also known as thiol proteases, are hydrolase enzymes that degrade proteins. These proteases share a common catalytic mechanism that involves a nucleophilic cysteine thiol in a catalytic triad or dyad. Discovered by Gopal Chunder Roy in 1873, the first cysteine protease to be isolated and characterized was papain, obtained from Carica papaya. Cysteine proteases are commonly encountered in fruits including the papaya, pineapple, fig, and kiwifruit. The proportion of protease tends to be higher when the fruit is unripe. In fact, the latex of dozens of different plant families are known to contain cysteine proteases. Cysteine proteases are used as an ingredient in meat tenderizers.
Le Havre experienced a population boom in the second half of the 19th century. Subsequently, the population drain of the First World War was offset by the annexation of the town of Graville (the city gained 27,215 people between 1911 and 1921). During the Second World War the population decreased significantly (a loss of 57,149 people between 1936 and 1946) because of the exodus and bombings. After the war the commune saw its population increase until 1975. Since then population has decreased again, especially between 1975 and 1982: during these years of industrial crisis the population fell by 18,494 people. The trend continued in the 1980s although at a slower pace. The current policy of the municipality is to build new housing to attract new residents with the goal of exceeding 200,000 inhabitants, a level that was reached in the 1960s. The population of the commune of Le Havre was 191,000 inhabitants in 1999 which placed the city at 12th place among the most populated cities in France and in the first place in Normandy. In 2022 INSEE counted 166,462 people living in the commune of Le Havre, while the urban area of Le Havre had 232,052 inhabitants and the metropolitan area of Le Havre had 335,499 inhabitants.
Transformation of a bacterial host with two different plasmids is required. One is designed to express a DNA-binding protein-of-interest as a fusion construct with a subunit of RNA polymerase (bait). The other plasmid contains a region of randomized sequence representing potential binding sites (prey) which, if bound to by the chimeric fusion product, drives expression of downstream reporter genes. This reporter region facilitates both positive and negative selection by HIS3 and URA3, respectively, which together allow for isolation of the prey containing the true DNA target sequence. HIS3 and URA3 encode proteins required for biosynthesis of histidine and uracil. Using a negative selectable marker is crucial for greatly reducing the incidence of false-positives. Self-activating prey, where the randomized region facilitate reporter expression in the absence of TF binding, are removed by transforming the reporter vector library into bacteria in the absence of bait and assaying for growth on plates containing 5-fluoro-orotic acid (5-FOA). The protein product of URA3 converts 5-FOA into a toxic compound, thereby allowing survival of only those colonies that contain reporter vectors which are not self-activating. Negative selection normally precedes positive selection so that a smaller, purified prey library can be subjected to the more rigorous positive selection process. Upon transformation of the purified prey library with the bait plasmid, positive selection is achieved by growing the host E.
PFAS contamination has also resulted in disruptions to the food supply, such as closures and limits on fishing. PFAS are brought to the Arctic from polluted southern waters by migrating birds. Although it is much less than compared to the introduction by wind and the oceans, the birds become vectors, transmitting the toxic chemicals. Rainer Lohmann, an oceanographer at the University of Rhode Island, noted that this has a significant localized affect that is devastating for Arctic predators who accumulate toxins in their bodies because the contaminants from the birds often enter the food chain directly since the birds are the prey of many species. Though fluorosurfactants with shorter carbon chains may be less prone to accumulating in mammals, there is still concern that they may be harmful to both humans and the environment.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.